Seroatlas · Human Serome Atlas

CGREF1

Cell growth regulator with EF hand domain protein 1

Also known as: CGR11, CGRE1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q99674
Gene: CGREF1
Ensembl: ENSG00000138028
Chromosome: 2
Canonical length: 318 aa
Protein class: Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins
Subcellular location: Golgi apparatus
Secretome location: Secreted in brain

OverviewNCBI Gene

Predicted to enable calcium ion binding activity. Predicted to be involved in negative regulation of cell population proliferation. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

318 residues, UniProt reviewed canonical sequence.

>Q99674|CGREF1
     1  MLPLTMTVLI LLLLPTGQAA PKDGVTRPDS EVQHQLLPNP FQPGQEQLGL LQSYLKGLGR
    61  TEVQLEHLSR EQVLLYLFAL HDYDQSGQLD GLELLSMLTA ALAPGAANSP TTNPVILIVD
   121  KVLETQDLNG DGLMTPAELI NFPGVALRHV EPGEPLAPSP QEPQAVGRQS LLAKSPLRQE
   181  TQEAPGPREE AKGQVEARRE SLDPVQEPGG QAEADGDVPG PRGEAEGQAE AKGDAPGPRG
   241  EAGGQAEAEG DAPGPRGEAG GQAEAEGDAP GPRGEAGGQA EARENGEEAK ELPGETLESK
   301  NTQNDFEVHI VQVENDEI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CGREF1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.59
Highest tissue expression: 45 nTPM

Expression across tissuesHPA

Tissue

basal ganglia: 45 nTPM
cerebral cortex: 38 nTPM
hippocampal formation: 33 nTPM
amygdala: 31 nTPM
cerebellum: 28 nTPM
hypothalamus: 27 nTPM

Single-cell type

oocytes: 281 nCPM
brain inhibitory neurons: 36 nCPM
brain excitatory neurons: 32 nCPM
other brain neurons: 32 nCPM
retinal amacrine cells: 28 nCPM
hepatic stellate cells: 26 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebral cortex: 58 nTPM
hippocampal formation: 55 nTPM
basal ganglia: 44 nTPM
amygdala: 41 nTPM
hypothalamus: 37 nTPM
cerebellum: 34 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.87
gnomAD pLI: 0
gnomAD missense Z: 1.04
DepMap mean gene effect: 0.1
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

calcium ion binding

Cellular components

extracellular region

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CGREF1 as an antibody target. Whether an autoantibody or antibody against CGREF1 could matter depends on whether native CGREF1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CGREF1 is annotated as secreted, so native CGREF1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label CGREF1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...